Allarity Therapeutics (NASDAQ:ALLR) versus Emerald Health Therapeutics (OTCMKTS:EMHTF) Head to Head Contrast

Emerald Health Therapeutics (OTCMKTS:EMHTF) and Allarity Therapeutics (NASDAQ:ALLR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Emerald Health Therapeutics and Allarity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emerald Health Therapeutics	N/A	N/A	N/A
Allarity Therapeutics	N/A	-109.94%	-47.27%

Analyst Recommendations

This is a summary of recent ratings for Emerald Health Therapeutics and Allarity Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emerald Health Therapeutics	0	0	0	0	0.00
Allarity Therapeutics	1	0	1	0	2.00

Allarity Therapeutics has a consensus target price of $10.25, indicating a potential upside of 682.44%. Given Allarity Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Emerald Health Therapeutics.

Earnings and Valuation

This table compares Emerald Health Therapeutics and Allarity Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emerald Health Therapeutics	N/A	N/A	N/A	N/A	N/A
Allarity Therapeutics	$320,000.00	65.13	-$11.23 million	($0.72)	-1.82

Emerald Health Therapeutics has higher earnings, but lower revenue than Allarity Therapeutics.

Institutional and Insider Ownership

11.5% of Allarity Therapeutics shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Allarity Therapeutics beats Emerald Health Therapeutics on 6 of the 8 factors compared between the two stocks.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production, distribution, and sale of recreational and medical cannabis in Canada. It offers dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products under the SYNC Wellness, fuse, Emerald, and Souvenir brands. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.